Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 20/20 | 0.78 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.78 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13631127 | 0.90 | TACR1 (0.84) | TACR1NR1I2 | |
| SCHEMBL4459562 | 0.90 | TACR1 (0.84) | TACR1NR1I2 | |
| SCHEMBL13631128 | 0.88 | TACR1 (0.74) | TACR1NR1I2 | |
| SCHEMBL4464116 | 0.87 | TACR1 (1.00) | TACR1NR1I2KCNH2 | |
| SCHEMBL4464112 | 0.87 | TACR1 (1.00) | TACR1NR1I2KCNH2 | |
| SCHEMBL4458861 | 0.87 | TACR1 (0.73) | TACR1NR1I2 | |
| SCHEMBL4470525 | 0.87 | TACR1 (0.91) | TACR1NR1I2KCNH2 | |
| SCHEMBL4470330 | 0.87 | TACR1 (0.91) | TACR1NR1I2KCNH2 | |
| SCHEMBL4458307 | 0.85 | TACR1 (0.69) | TACR1NR1I2 | |
| SCHEMBL4471294 | 0.85 | TACR1 (1.00) | TACR1NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286777-A1 | 5,6,Fused Pyrrolidine Compounds Useful as Tachykinin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-11-19 | — | — | US | disclosed |
| US-20090286777-A1 | 5,6,Fused Pyrrolidine Compounds Useful as Tachykinin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-11-19 | — | — | US | disclosed |
| US-20090286777-A1 | 5,6,Fused Pyrrolidine Compounds Useful as Tachykinin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-11-19 | — | — | US | disclosed |
| WO-2007136570-A2 | 5,6-FUSED PYRROLIDINE COMPOUNDS USEFUL AS TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286777-A1 | 5,6,Fused Pyrrolidine Compounds Useful as Tachykinin Receptor Antagonists | TACR1, TACR2, NPSR1 | TACR1 1/4885NR1I2 2873/4885KCNH2 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.